Abivax (ABVX) Liabilities and Shareholders Equity (2021 - 2026)

Abivax's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $640.6 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 264.78% year-over-year to $640.6 million; the TTM figure through Mar 2026 stood at $2.2 billion (up 216.36% YoY), while the FY2025 annual figure was $680.2 million, up 210.2% from the prior year.
• Liabilities and Shareholders Equity was $640.6 million for Q1 2026 at Abivax, down from $680.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $762.3 million in Q3 2025 to a low of $77.1 million in Q4 2022.
• Historically, Liabilities and Shareholders Equity has averaged $372.1 million across 5 years, with a median of $306.4 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity surged 356.58% in 2023, then tumbled 55.8% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $77.1 million in 2022, then soared by 356.58% to $351.9 million in 2023, then sank by 37.69% to $219.3 million in 2024, then soared by 210.2% to $680.2 million in 2025, then fell by 5.83% to $640.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $640.6 million (Q1 2026), $680.2 million (Q4 2025), and $762.3 million (Q3 2025), per Business Quant data.